Cariprazine in the management of negative symptoms of schizophrenia: State of the art and future perspectives

Christoph U. Correll, Koen Demyttenaere, Andrea Fagiolini, Göran Hajak, Stefano Pallanti, Giorgio Racagni, Swaran Singh

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

In schizophrenia, dopaminergic hyperactivity in the mesolimbic regions, or possibly even selectively so in the dorsal striatum, seems to cause the emergence of psychotic symptoms, whereas dopaminergic hypoactivity in cortical regions underlies the negative symptoms and cognitive deficits. Managing the negative symptoms is a major current challenge in the treatment of schizophrenia with a dearth of novel modalities to address this clinical issue. Cariprazine is a novel second-generation antipsychotic that specifically targets the D3 receptor mainly associated to negative symptoms. The review summarizes the main issues regarding negative symptom management and the role of cariprazine treatment.

Original languageEnglish
Article number0012
JournalFuture Neurology
Volume15
Issue number4
DOIs
StatePublished - Nov 2020
Externally publishedYes

Keywords

  • D3 receptor
  • cariprazine
  • dopamine
  • negative symptoms
  • partial agonist
  • schizophrenia

Fingerprint

Dive into the research topics of 'Cariprazine in the management of negative symptoms of schizophrenia: State of the art and future perspectives'. Together they form a unique fingerprint.

Cite this